Research programme: Alzheimer's disease therapeutics - Eisai

Drug Profile

Research programme: Alzheimer's disease therapeutics - Eisai

Alternative Names: AD genetics programme - Eisai; Alzheimer's disease genetics programme - Eisai

Latest Information Update: 25 May 2010

Price : $50

At a glance

  • Originator TorreyPines Therapeutics Inc
  • Developer Eisai Co Ltd
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 10 Nov 2008 TorreyPines Therapeutics sells its Alzheimer's disease genetics programme to Eisai
  • 22 Oct 2008 TorreyPines Therapeutics is actively seeking to sell/out-license this research programme (http://www.torreypinestherapeutics.com)
  • 28 Sep 2007 Eisai and TorreyPines Therapeutics extend their existing genetics discovery collaboration in Alzheimer's disease for an additional year
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top